Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target Cut to $3.50 by Analysts at HC Wainwright

Adaptimmune Therapeutics (NASDAQ:ADAP) had its price objective cut by HC Wainwright from $4.00 to $3.50 in a report issued on Thursday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Adaptimmune Therapeutics’ Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.12) EPS.

Separately, StockNews.com raised shares of Adaptimmune Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 13th.

Adaptimmune Therapeutics Price Performance

Shares of Adaptimmune Therapeutics stock traded up $0.00 during trading on Thursday, reaching $0.59. 2,817,898 shares of the company’s stock were exchanged, compared to its average volume of 1,694,537. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.09 and a quick ratio of 3.09. Adaptimmune Therapeutics has a 1-year low of $0.42 and a 1-year high of $2.05. The firm’s 50-day moving average price is $0.89 and its 200 day moving average price is $1.04.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its earnings results on Monday, August 12th. The biotechnology company reported $0.27 earnings per share for the quarter. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 83.38%. The firm had revenue of $128.23 million for the quarter, compared to analysts’ expectations of $58.00 million. As a group, analysts forecast that Adaptimmune Therapeutics will post -0.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Institutional investors have recently bought and sold shares of the company. Long Focus Capital Management LLC raised its stake in shares of Adaptimmune Therapeutics by 15.6% in the second quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock valued at $12,037,000 after buying an additional 1,662,184 shares during the period. Baillie Gifford & Co. increased its stake in shares of Adaptimmune Therapeutics by 10.7% in the third quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock worth $15,944,000 after purchasing an additional 1,626,657 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Adaptimmune Therapeutics by 28.3% in the second quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock worth $1,742,000 after acquiring an additional 394,566 shares during the period. Vontobel Holding Ltd. increased its position in shares of Adaptimmune Therapeutics by 230.8% during the third quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 30,000 shares during the period. Finally, Fullcircle Wealth LLC purchased a new stake in shares of Adaptimmune Therapeutics in the third quarter worth about $33,000. Hedge funds and other institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.